Price: quote on request. Your total cost is quoted in writing per case.
We give you a written timeline estimate for your case before you commit.
Ask about treatment

Immune thrombocytopenia (ITP): US-approved treatments and how families in the Gulf can access them

A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Immune thrombocytopenia (ITP): the short answer

The US FDA has approved five medicines covered on this page for immune thrombocytopenia (ITP), each for a specific group of patients: Nplate, Promacta, Doptelet Sprinkle, Tavalisse and Wayrilz. On 17 October 2026, five of them were on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.

  • US FDA-approved medicines on this page: Nplate, Promacta, Doptelet Sprinkle, Tavalisse and Wayrilz.
  • Gulf registers (checked 17 October 2026): see each medicine below.
  • Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
  • Price: Quote on request.

What is immune thrombocytopenia (ITP)?

Immune thrombocytopenia (ITP) is a platelet disorder in which the blood does not clot as it should because of a low platelet count. Platelets normally stick together to plug a wound, so people with ITP may have trouble stopping bleeding.[1]

ITP can be acute or chronic. Acute ITP often lasts less than 12 months, mainly affects children and is the most common type. Chronic ITP lasts 12 months or longer and mostly affects adults, women two to three times more often than men.[1]

ITP may cause no symptoms, or it may cause bleeding that is hard to stop, such as small red spots under the skin. When first treatments are not enough, several medicines are approved in the US for chronic ITP.[1, 2, 3]

Immune thrombocytopenia (ITP) in the Gulf

Gulf hematology studies include a study of ethnicity and the response to eltrombopag in ITP in Qatar (2022), a review of three decades of managing childhood ITP in Arab countries (2013), and a 2026 study of maternal and neonatal outcomes of ITP in pregnancy.[4, 5, 6]

We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 4 of 5 were listed in Saudi Arabia and 5 of 5 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[7, 8]

US FDA-approved medicines for immune thrombocytopenia (ITP)

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

  • Nplate (romiplostim)
    US FDA-approved for adults with ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy, and children with ITP as set out in its label. It is a weekly injection under the skin.[2]
    Current US label version: 23 June 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[7, 8]
    Country access guides: Saudi Arabia, UAE, Egypt, India
  • Promacta (eltrombopag)
    US FDA-approved for persistent or chronic ITP in adults and children 1 year and older after an insufficient response to corticosteroids, immunoglobulins or splenectomy. It is a tablet, sold as Revolade outside the US.[3]
    Current US label version: 18 December 2025. Gulf registers: Saudi Arabia (SFDA drugs list): listed as Revolade. Abu Dhabi (DoH drug code list): listed as Revolade. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[7, 8]
  • Doptelet Sprinkle (avatrombopag)
    US FDA-approved for adults with chronic ITP after an insufficient response to a previous treatment, and children 1 year and older with persistent or chronic ITP. It is a tablet.[9]
    Current US label version: 13 August 2025. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[7, 8]
    Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
  • Tavalisse (fostamatinib)
    US FDA-approved for adults with chronic ITP after an insufficient response to a previous treatment. It is a tablet.[10]
    Current US label version: 5 November 2025. Gulf registers: Saudi Arabia (SFDA drugs list): listed as Tavlesse. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[7, 8]
    Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
  • Wayrilz (rilzabrutinib)
    US FDA-approved for adults with persistent or chronic ITP after an insufficient response to a previous treatment. It is a BTK inhibitor tablet.[11]
    Current US label version: 26 August 2025. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[7, 8]
    Country access guides: Qatar, Lebanon, Turkey

How families in the Gulf can access treatment

If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[12, 13] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.

Who does what

  • Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
  • The hospital checks local supply, files any import request, and gives the treatment safely.
  • The national regulator decides whether to approve the import of a medicine that is not registered.
  • The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
  • Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

  • A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
  • Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
  • Recent clinic notes and a list of current medicines
  • For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
  • Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for immune thrombocytopenia (ITP)

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Include the country code, for example +966 or +971.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for immune thrombocytopenia (ITP)?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Nplate, Promacta, Doptelet Sprinkle, Tavalisse and Wayrilz. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Nplate available in Saudi Arabia or the UAE?

We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.

How can a family in the Gulf get Nplate?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

Which ITP medicines are approved for children?

Promacta and Doptelet are approved for children 1 year and older with persistent or chronic ITP, and Nplate also has a pediatric indication in its label. Tavalisse and Wayrilz are for adults.

Sources for the condition-specific answers: [3, 9, 2]

Sources

Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.

  1. National Heart, Lung, and Blood Institute (NHLBI): Platelet Disorders
  2. DailyMed: NPLATE (romiplostim) US prescribing information, label version 23 June 2026
  3. DailyMed: PROMACTA (eltrombopag) US prescribing information, label version 18 December 2025
  4. Yassin MA, et al. The Impact of Ethnicity on the Response to Eltrombopag in Patients With Immune Thrombocytopenia (ITP) in Qatar: A Single Institution Experience. Cureus. 2022 (PubMed 35812564)
  5. Elalfy MS, et al. Three decades of experience in managing immune thrombocytopenia in children in Arab countries. Semin Hematol. 2013 (PubMed 23664511)
  6. Elkorashi S, et al. Maternal and Neonatal Outcomes of Immune Thrombocytopenia in Pregnancy: A Five-Year Single-Center Cross-Sectional Study. Health Sci Rep. 2026 (PubMed 42291716)
  7. SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
  8. Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
  9. DailyMed: DOPTELET SPRINKLE (avatrombopag) US prescribing information, label version 13 August 2025
  10. DailyMed: TAVALISSE (fostamatinib) US prescribing information, label version 5 November 2025
  11. DailyMed: WAYRILZ (rilzabrutinib) US prescribing information, label version 26 August 2025
  12. SFDA: Special Access Program (SAP) guidance, version 1.0
  13. NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products

Related

This page is general health information, not medical advice. It does not replace a consultation with your doctor.

WhatsApp